Transferrin as a Predictor of Survival in Cirrhosis

André Viveiros[1], Armin Finkenstedt[1], Benedikt Schaefer[1], Mattias Mandorfer[3], Bernhard Scheiner[3], Konrad Lehner[1], Moritz Tobiasch[1], Thomas Reiberger[3], Herbert Tilg[1], Michael Edlinger[2], Heinz Zoller[1]

[1]Department of Medicine, Medical University and University Hospital of Innsbruck, Anichstrasse 35 A-6020 Innsbruck, Austria

[2]Department of Medical Statistics, Informatics, and Health Economics, Medical University Innsbruck, Schöpfstrasse 41/1, A-6020 Innsbruck, Austria

[3]Department of Medicine III, Division of Gastroenterology & Hepatology, Medical University of Vienna, Waehringer Guertel 18-20, A-1020 Vienna, Austria

Corresponding authors:

Dr. Heinz Zoller

Medical University and University Hospital of Innsbruck

Department of Medicine

Anichstrasse 35

Dr. Michael Edlinger

Medical University Innsbruck

Department of Medical Statistics, Informatics, and Health Economics

Schöpfstrasse 41/1

A-6020 Innsbruck

Austria

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/lt.24981

Abstract

Background and aims: Patients with cirrhosis frequently present with high serum ferritin and low transferrin concentrations, reflecting impaired liver function and inflammation. Recent studies have shown that transferrin and its saturation with iron are MELD-independent predictors of mortality in patients with acute on chronic liver failure or decompensated cirrhosis. The aim of this study was to evaluate the prognostic utility of serum iron parameters in relation to markers of liver function and immune activation.

Methods: Clinical, demographic and biochemical data were retrospectively analyzed from a cohort of 1255 consecutive patients with cirrhosis (age ≥ 18 years) who presented from August 1st 2004 till December 31st 2014 at the University Hospital of Innsbruck. Patients with malignancies at diagnosis including hepatocellular carcinoma were excluded. Survival analysis was carried out by Cox regression using baseline laboratory parameters and findings were validated in an independent patient cohort.

Results: During a median follow-up of 2.41 years, 193 deaths occurred and 254 patients underwent liver transplantation. In patients with transferrin < 180 mg/dL, 3-month, 1-year and 5-year transplant-free survival estimates were significantly lower (91.7%, 79.0% and 30.5%) when compared with the group of patients with transferrin ≥ 180 mg/dL (98.9%, 95.5% and 68.0%, P < .001). Transferrin predicted transplant-free survival independently of MELD-Na and C-reactive protein (CRP) in multivariable regression analysis including all patients. When patients with alcoholic or non-alcoholic fatty liver disease were excluded, transferrin was in addition an albumin-independent predictor of transplant-free survival.

Conclusion: In conclusion, the association of transferrin with transplant-free survival is independent of MELD-Na score and CRP. In patients without fatty liver disease transferrin also predicts survival independently of albumin.

Introduction

The model for end-stage liver disease (MELD) has evolved as a reference staging system for cirrhosis and is used for prognosis, evaluation for liver transplantation and donor liver allocation[1-3]. Incorporating sodium, age or albumin into modified MELD scores improves accuracy in predicting survival in patients with cirrhosis[4-8]. In search for additional prognostic parameters, high ferritin at the time of listing for liver transplantation was identified as an independent predictor of waiting list mortality[9], but the prognostic utility of ferritin could not be reproduced in a larger cohort[10]. When transferrin saturation was taken into consideration, ferritin could predict mortality on the waiting list and after orthotopic liver transplantation[11].

Iron overload was therefore proposed as a risk factor for mortality in patients with liver disease. Accordingly, transferrin and transferrin saturation have also been identified as predictors of survival in patients with decompensated cirrhosis and acute-on-chronic liver failure (AoCLF)[12, 13]. Transferrin is lower in patients with cirrhosis and impaired synthetic function[14]. High ferritin and low transferrin can indicate inflammation[15, 16], which is also a risk factor for disease progression and mortality in cirrhosis. In addition, alcohol and metabolic factors can directly affect iron metabolism[17-19]. Hence, it remains unclear if altered iron metabolism is cause or consequence of advanced liver disease in different etiologies.

The effect of inflammation and hepatic function on serum iron parameters was assessed by correlating serum ferritin, transferrin and transferrin saturation with C-reactive protein (CRP) and albumin. The prognostic utility of all these parameters was determined by survival analysis in a large cohort of unselected patients with cirrhosis.

Patients and Methods

Patient demographics and laboratory data

Derivation cohort

From a cohort of consecutive 1437 patients (age ≥ 18 years) with liver cirrhosis who presented from August 1st 2004 to December 31st 2014 at the University Hospital of Innsbruck, 182 patients with hepatocellular carcinoma or other malignancy at diagnosis were excluded, resulting in a final study cohort of 1255 patients (Figure 1). Diagnosis of cirrhosis was made according to clinical, biochemical, and imaging criteria[20]. We received ethical approval by the ethic committee of the Medical University of Innsbruck to conduct this study.

Clinical, demographic and biochemical data were collected by retrospective review of patient charts. MELD score was calculated according to the United Network for Organ Sharing (UNOS) model, in which a MELD score over 11 requires serum sodium correction (MELD-Na)[3, 6, 7].

The majority of patients (79% - 989 patients) were outpatients. The remaining 266 patients were hospitalized; 65 of whom (5%) were treated in an intermediate care unit. The start date of this cohort corresponds to the first assessment of serum iron parameters, and study endpoints were death, liver transplantation or last follow-up. Accordingly, prognosis was calculated using 3-month, 1-year, and 5-year transplant-free survival, in which patients who underwent liver transplantation or were lost to follow-up were right-censored.

Validation cohort

In order to validate the results of this investigation, a cohort of 596 unselected cirrhotic patients was included in the two study centers Innsbruck (302 patients) and Vienna (294 patients) from January 1st 2004 to March 31st 2016 Inclusion criteria were identical to those applied to the derivation cohort.

Statistical analysis

IBM SPSS Statistics version 22.0.0.1 (IBM Corp., Armonk, NY) and MedCalc, version 17.7.2 (MedCalc Software, Ostend, Belgium) were used for statistical analysis and a significance value of 0.05 was considered in all statistic tests. Kolmogorow-Smirnow test was used to test normality of distribution. Not normally distributed variables were reanalyzed after logarithmic transformation. Continuous variables were reported using median and interquartile range and analyzed using Student's t-test or the Mann Whitney U test, as appropriate. Categorical variables were expressed in frequencies (with percentages in parenthesis) and tested for significance using the χ^2 test or the Fisher's exact test. Survival models were built based on univariable and multivariable Cox regression analysis. For survival analysis 3-month, 1-year, and 5-year transplant free survival rates were analyzed. Receiver operating characteristic (ROC) calculations were performed and the Youden index was applied to calculate the optimal transferrin cut-off point. Kaplan-Meier analysis was then carried out to determine survival according to transferrin levels and groups were compared using the log-rank test. Correlation analysis for transferrin, CRP and albumin were carried out using the Spearman's rank correlation coefficient as all three variables did not show a normal distribution.

Results

To determine whether transferrin is a predictor of survival in unselected patients with cirrhosis, clinical and biochemical parameters were retrospectively assessed in a cohort of 1255 cirrhosis patients. During a median follow-up of 2.4 years (95% CI 0.1 – 9.0), 193 (15%) deaths occurred and 254 patients underwent liver transplantation (20%). For validation, an independent cohort of patients was recruited at the liver centers in Innsbruck and Vienna. Baseline patient characteristics of the derivation and validation cohort are shown in Table 1.

Univariable Cox regression analysis showed that ferritin, transferrin and transferrin saturation, but not serum iron were significantly associated with transplant-free survival. Of all serum iron parameters, transferrin is the only independent predictor of survival in the derivation and validation cohort (Table 2).

ROC curve analysis showed that the best cut-off for transferrin to predict 3-month transplant-free survival is 180 mg/dL (Figure 2). The 3-month, 1-year and 5-year transplant-free survival estimates were significantly lower in the group of patients with transferrin < 180 mg/dL (91.7%, 70.0% and 30.5%) when compared with the group of patients with transferrin > 180 mg/dL (98.9%, 95.5% and 68.0%, Table 3 and Figure 3A). Stratification based on transferrin also showed that patients with transferrin < 180 mg/dL were more likely to be male and have cirrhosis due to alcoholic (ALD) or non-alcoholic fatty liver disease (NAFLD) as an underlying etiology. Patients with low transferrin also had more advanced liver disease (higher MELD-Na score), higher white cell count and higher levels of CRP (Table 3).

To test if etiology had an impact on the predictive power of transferrin we next grouped patients according to underlying disease. This analysis showed that transplant-free survival was not significantly different in the ALD or NAFLD associated cirrhosis group when compared with all other etiologies (log rank P = 0.096). Transferrin independently predicted transplant-free survival in the group of patients with cirrhosis caused by diseases other than ALD or NAFLD (HR .988, 95% CI .985 –

.992, *P* < .001). Individual subgroup analysis for patients with ALD or NAFLD showed that transferrin was significantly associated with transplant-free survival (ALD: HR .535, 95% CI .318 – .900, *P* = .019 and NAFLD: HR .572, 95% CI .443 – .739, *P* < .001), but this association was lost for both subgroups when MELD or MELD-Na was added to a multivariable model (data not shown).

To further study the impact of cirrhosis stage on the utility of transferrin for prognosis, we analyzed patient subgroups with MELD-Na ≥ 15 and patients with MELD-Na < 15, which is the accepted cutoff for transplant evaluation[21]. As shown in Figure 3B, transplant-free survival was significantly higher in patients with transferrin > 180 mg/dL in the cohort with a MELD-Na score < 15 (*P* < 0.001). In the group of patients with MELD-Na score ≥ 15 this association was lost, showing that transferrin is a better predictor of survival at earlier liver disease stages (Figure 3C).

Next, the effect of inflammation on transferrin concentration and its association with mortality were assessed using CRP as a surrogate parameter. Figure 4 shows a non-linear but significantly negative correlation between transferrin and CRP, which confirms that transferrin is a negative acute phase reactant. As shown in Table 2, multivariable Cox regression analysis including all patients showed a stronger prediction of mortality for transferrin than for CRP. These results were confirmed in the validation cohort.

To assess the interactions between hepatic synthetic function and transferrin, albumin was next included in the analysis. Pearson correlation showed a stronger and linear association between transferrin and albumin (Figure 4B). Multivariable Cox regression analysis including albumin revealed different results for the derivation and validation cohort. In search for factors accounting for these differences, patients were grouped by disease stage (MELD-Na cutoff 15) or by etiology. As shown in Table 4 and in accordance with previous studies[22], MELD-Na is a poor predictor of survival in patients with early cirrhosis (MELD-Na < 15). In this patient group, albumin remained the only independent predictor of survival in the derivation and validation cohort. When patients with ALD or NAFLD were excluded, on the basis that alcohol and metabolic syndrome directly affect serum iron parameters,

transferrin was a predictor of transplant-free survival independently of MELD-Na, CRP and albumin in both cohorts (Table 5).

Discussion

Beyond the immediate implications for predicting outcomes, studying prognostic factors in patients with cirrhosis helps improving our understanding of disease pathogenesis and could ultimately lead to the identification of new therapeutic targets. Recent studies have shown that serum iron parameters are independent predictors of survival in patients awaiting liver transplantation, AoCLF and critically ill patients[11-13, 23]. A main finding of this study is that of all serum iron parameters, transferrin is the best prognostic parameter and independent of MELD-Na.. In contrast to the AoCLF cohort, where the best cutoff for transferrin was 87 mg/dL, the best predictive power of transferrin in our cohort for a 3 months- and 1 year- survival was 180 mg/dL. This highlights both the severity of alterations in iron metabolism in AoCLF, as well as the need to individualize cutoffs according to disease stage.

Reduced transferrin concentration in patients with cirrhosis can be attributed to impaired hepatic function, inflammation, alcohol consumption or metabolic syndrome. In our study transferrin correlates significantly with CRP, but predicts survival independently of inflammation. In contrast, transferrin does not predict transplant-free survival independently of albumin. In patients with MELD-Na < 15, where this established score has poor discriminative accuracy[22], albumin remained the best predictor of survival in both cohorts. When alcohol and metabolic effects were excluded from the model, by selecting only patients with viral, genetic, cholestatic and autoimmune etiology, transferrin was confirmed as a predictor of transplant-free survival independently of MELD-Na, CRP and albumin. The finding that patients with fatty liver disease have significantly lower transferrin concentration, confirms that alcohol and metabolic factors directly suppress transferrin synthesis. This effect could explain why albumin is a stronger predictor of survival than transferrin when also patients with fatty liver disease are included in the survival analysis.

Association studies cannot discern if altered serum iron parameters are a mere consequence or a driver of disease progression in patients with cirrhosis. Regardless of the exact hierarchy of events, excess iron will impair different immune effector functions and can induce ferropotosis - a recently

identified form of programmed cell death triggered by iron[24, 25]. Toxic non-transferrin bound iron (NTBI) species increase when plasma transferrin concentration decreases and are specifically taken up by hepatocytes[26]. Accordingly, hepatic iron overload has been histologically reported in 32.4% of patients with end stage liver disease[27]. Impaired hepatocellular function has also been associated with decreased hepcidin production, which can lead to uncontrolled release of iron from cells. Reduced plasma iron binding capacity and increased iron release in cirrhosis could therefore promote hepatocellular iron toxicity in cirrhosis. The results from our study support the hypothesis that increasing iron binding capacity in plasma could improve survival in patients with cirrhosis. This can be achieved by administering apo-transferrin[28] or hepcidin agonists, which are currently in clinical development[29].

In conclusion, our study shows that transferrin predicts transplant-free survival independently of MELD-Na score in unselected patients with cirrhosis. Regardless of etiology and cirrhosis stage, transferrin ≥ 180 mg/dL is associated with significantly better prognosis. More complex survival modeling in this large cohort shows that the prognostic value of transferrin is independent of inflammation. Albumin appears to be a stronger predictor of survival than transferrin in patients with ALD and NAFLD. The albumin-independent association of transferrin with survival in patients without fatty liver disease confirms that alcohol and metabolic factors represent an additional burden on iron metabolism and influence how serum iron parameters predict survival in patients with cirrhosis.

Abbreviations

ALD, alcoholic fatty liver disease; AoCLF, acute-on-chronic liver failure; CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; HCC, hepatocellular carcinoma; LPI, labile plasma iron; MELD, model for end-stage liver disease; NAFLD, non-alcoholic fatty liver disease; NTBI, non-transferrin bound iron; UNOS, United Network for Organ Sharing; ROC, receiver operating characteristic.

Tables and Figures

Table 1. Clinical characteristics and outcome of patients stratified according to MELD score.

	Derivation cohort (n=1255)	Validation cohort (n=596)	*P* value
Age, years	57 (49 – 64)	55 (48 – 63)	.002
Females/males, n (%)	404/851 (32.2/67.8)	166/430 (27.9/72.1)	.06
Underlying liver disease, n (%)			
ALD	222 (17.7)	21 (3.5)	
NAFLD	563 (44.9)	121 (20.3)	
HBV/HCV	254 (20.2)	140 (23.5)	
Cryptogenic	80 (6.4)	5 (.8)	< .001
Biliary (PSC/PBC)	52 (4.1)	45 (7.6)	
Autoimmune	26 (2.1)	66 (11.1)	
Metabolic (HH/α1-ATD/Wilson)	23 (1.8)	94 (15.8)	
Other	35 (2.8)	104 (17.4)	
White cell count, G/L	6.0 (4.4 – 7.8)*	-	-
Hemoglobin, g/L	123 (107 – 140)*	-	-
Platelet count, G/L	116 (75.8 – 168)*	-	-
CRP, mg/dL	.60 (.21 – 1.42)	0.35 (0.11 – 1.18)	< .001
Albumin, mg/dL	3530 (2998 – 4080)	3630 (3093 – 4082)	.07
Creatinine, mg/dL	.84 (.68 – 1.06)	0.84 (0.72 – 0.10)	.94
MELD-Na score	13 (9 – 18)	11 (8 – 17)	< .001
Bilirubin, mg/dL	1.61 (0.90 – 3.09)	1.24 (0.78 – 2.59)	< .001
INR	1.3 (1.1 – 1.5)	1.3 (1.1 – 1.44)	.001
Sodium, mmol/L	138 (135 – 140)	138 (135 – 140)	.53
Serum iron, µmol/L	17.6 (10.3 – 25.9)	19.8 (11.4 – 27.8)	.005
Serum ferritin, µg/L	204 (70 – 510)	215 (68 – 596)	.18
Transferrin, mg/dL	232 (170 – 285)	248 (180 – 295)	.005
Transferrin saturation, %	32 (17 – 54)	33 (20 – 57)	.20
3-month transplant-free survival rate, % (n)	97.0 (1085/1118)	95.9 (534/557)	.25
1-year transplant-free survival rate, %(n)	91.6 (779/850)	86.2 (413/479)	.002
5-year transplant-free survival rate, %(n)	58.8 (227/386)	49.5 (147/297)	.002

For continuous variables, median values are represented and the 25th and 75th percentiles are given between parentheses. The number and percent of patients are shown for categorical variables. *n=1254

Table 2. Uni- and multivariable Cox regression: serum iron parameters.

	Derivation cohort (n=1255)				Validation cohort (n=596)			
	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value
Age (years)	1.023 (1.010 – 1.036)	< .001	1.026 (1.013 – 1.040)	< .001	1.047 (1.033 – 1.061)	< .001	1.047 (1.033 – 1.062)	< .001
Serum iron (µmol/L)	.995 (.982 – 1.008)	.47	-	-	.991 (.978 – 1.003)	.14	-	-
Serum ferritin (g/L)	1.038 (1.021 – 1.054)	< .001	1.008 (.983 – 1.035)	.54	1.010 (.999 – 1.021)	.07	1.000 (.983 – 1.016)	.95
Transferrin (g/L)	.496 (.411 – .598)	< .001	.563 (.419 – .755)	< .001	.498 (.413 – .600)	< .001	.522 (.406 – .672)	< .001
Transferrin saturation (%)	1.011 (1.006 – 1.017)	< .001	1.005 (.994 – 1.016)	.37	1.006 (1.002 – 1.010)	.002	1.002 (.996 – 1.008)	.53

Table 3. Uni- and multivariable Cox regression: iron and inflammation.

	Derivation cohort				Validation cohort			
	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value
Model A: all patients	n=1255				n=596			
Age (years)	1.023 (1.010 – 1.036)	< .001	1.031 (1.018 – 1.044)	< .001	1.047 (1.033 – 1.061)	< .001	1.044 (1.030 – 1.059)	< .001
MELD-Na score	1.122 (1.097 – 1.148)	< .001	1.104 (1.075 – 1.134)	< .001	1.084 (1.065 – 1.104)	< .001	1.058 (1.034 – 1.083)	< .001
CRP (mg/dL)	1.127 (1.078 – 1.179)	< .001	1.036 (.975 – 1.102)	.26	1.088 (1.048 – 1.129)	< .001	1.044 (.993 – 1.097)	.09
Transferrin (g/L)	.496 (.411 – .598)	< .001	.735 (.592 - .913)	.005	.498 (.413 - .600)	< .001	.654 (.524 - .816)	< .001

Table 4. Clinical characteristics and outcome of patients stratified according to transferrin concentration.

	Derivation cohort			Validation cohort		
	Transferrin < 180 mg/dL (n=352)	**Transferrin ≥ 180 mg/dL (n=903)**	***P* value**	**Transferrin < 180 mg/dL (n=147)**	**Transferrin ≥ 180 mg/dL (n=449)**	***P* value**
Age, years	56 (48 – 63)	57 (49 – 64)	.16	56 (49 – 64)	54 (47 – 62)	.08
Females/males, n (%)	96/256 (27.3/72.7)	308/595 (34.1/65.9)	.02	36/111 (24.5 – 75.5)	130/319 (29.0 – 71.0)	.30
Underlying liver disease, n (%)						
ALD	89 (25.3)	133 (14.7)		5 (3.4)	16 (3.6)	
NAFLD	177 (50.3)	386 (42.7)		31 (21.1)	90 (20.0)	
HBV/HCV	40 (11.4)	214 (23.7)		14 (9.5)	126 (28.1)	
Cryptogenic	20 (5.7)	60 (6.6)	< .001	2 (1.4)	3 (.7)	< .001
Biliary (PSC/PBC)	3 (.9)	49 (5.4)		14 (9.5)	31 (6.9)	
Autoimmune	4 (1.1)	22 (2.4)		11 (7.5)	55 (12.2)	
Metabolic (HH/α1-ATD/Wilson)	10 (2.8)	13 (1.4)		37 (25.2)	57 (12.7)	
Other	9 (2.6)	26 (2.9)		33 (22.4)	71 (15.8)	
White cell count, G/L	7.0 (5.1 – 9.1)*	5.6 (4.3 – 7.2)	< .001	-	-	-
Hemoglobin, g/L	111 (98 – 124)*	128 (113 – 144)	< .001	-	-	-
Platelet count, G/L	105 (69 – 150)*	118 (77 – 171)	.01	-	-	-
CRP, mg/dL	1.54 (.86 – 3.28)	.38 (.14 – .93)	< .001	1.28 (.49 – 2.74)	.23 (.10 – .64)	< .001
Albumin, mg/dL	2950 (2520 – 3470)	3740 (3250 – 4210)	< .001	3070 (2700 – 3440)	3780 (3320 – 4195)	< .001
Creatinine, mg/dL	.88 (.66 – 1.26)	.83 (.68 – 1.00)	.001	.86 (.72 – 1.12)	.83 (.71 – .96)	.04
MELD-Na score	19 (15 – 25)	12 (9 – 15)	< .001	19 (15 – 24)	10 (8 – 14)	< .001
Bilirubin, mg/dL	3.35 (1.72 – 6.27)	1.27 (0.79 – 2.21)	<.001	3.38 (1.69 – 6.82)	1.04 (.74 – 1.79)	< .001
INR	1.5 (1.3 – 1.7)	1.2 (1.1 – 1.4)	< .001	1.5 (1.3 – 1.8)	1.2 (1.1 – 1.3)	< .001
Sodium, mmol/L	135 (131 – 138)	139 (136 – 141)	< .001	135 (132 – 138)	138 (136 – 140)	< .001
Serum iron, µmol/L	17.1 (10.7 – 24.6)	17.7 (10.3 – 26.3)	0.21	19.8 (11.6 – 26.9)	19.8 (11.3 – 28.1)	.69
Serum ferritin, µg/L	540 (245 – 1031)	141 (48 – 310)	< .001	660 (286 – 1344)	153 (50 – 420)	< .001
Transferrin, mg/dL	136.5 (106 – 160)	261 (226 – 303)	< .001	136 (103 – 160)	272 (234 – 315)	< .001
Transferrin saturation, %	58 (32 – 84)	27 (15 – 42)	<.001	65 (36 – 88)	28 (17 – 44)	< .001
3-month transplant-free survival rate, % (n)	91.7 (265/289)	98.9 (820/829)	< .001	83.5 (106/127)	99.5 (428/430)	< .001
1-year transplant-free survival rate, % (n)	79.0(158/200)	95.5 (621/650)	< .001	62.6 (62/99)	92.4 (351/380)	< .001
5-year transplant-free survival rate, % (n)	30.5 (29/95)	68.0 (198/291)	< .001	20.5 (15/73)	58.9 (132/224)	< .001

For continuous variables, median values are represented and the 25th and 75th percentiles are given between parentheses. The number and percent of patients are shown for categorical variables.. *n=351

Table 5. Uni- and multivariable Cox regression: iron, inflammation and hepatic function at different cirrhosis stages.

	Derivation cohort				Validation cohort			
	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value
Model A: all patients		**n=1255**				**n=596**		
Age (years)	1.023 (1.010 – 1.036)	< .001	1.035 (1.021 – 1.049)	< .001	1.047 (1.033 – 1.061)	< .001	1.042 (1.028 – 1.056)	< .001
MELD-Na score	1.122 (1.097 – 1.148)	< .001	1.096 (1.066 – 1.127)	< .001	1.084 (1.065 – 1.104)	< .001	1.047 (1.021 – 1.074)	< .001
CRP (mg/dL)	1.127 (1.078 – 1.179)	< .001	1.020 (.958 – 1.087)	.53	1.088 (1.048 – 1.129)	< .001	1.022 (.971 – 1.076)	.41
Albumin (g/L)	.921 (.903 – .940)	< .001	.949 (.926 – .973)	< .001	.914 (.894 - .934)	< .001	.955 (.930 – .981)	.001
Transferrin (g/L)	.496 (.411 – .598)	< .001	.917 (.725 – 1.160)	.47	.498 (.413 – .600)	< .001	.750 (.593 - .948)	.02
Model B: MELD-Na < 15		**n=731**				**n=404**		
Age (years)	1.024 (1.006 – 1.042)	.009	1.022 (1.004 – 1.040)	.02	1.044 (1.027 – 1.062)	< .001	1.041 (1.024 – 1.058)	< .001
MELD-Na score	1.144 (1.057 – 1.239)	.001	1.075 (.986 – 1.171)	.10	1.153 (1.068 – 1.244)	< .001	1.071 (.986 – 1.163)	.10
CRP (mg/dL)	1.164 (1.065 – 1.271)	.001	1.060 (.946 – 1.188)	.32	1.105 (1.035 – 1.180)	.003	1.071 (.990 – 1.159)	.09
Albumin (g/L)	.925 (.899 – .953)	< .001	.952 (.919 – .985)	.005	.900 (.872 – .929)	< .001	.913 (.881 – .946)	< .001
Transferrin (g/L)	.473 (.343 – .654)	< .001	.689 (.485 – .980)	.04	.613 (.456 – .823)	.001	.842 (.614 – 1.155)	.29
Model C: MELD-Na ≥ 15		**n=524**				**n=192**		
Age (years)	1.031 (1.012 – 1.051)	.001	1.044 (1.023 – 1.065)	< .001	1.043 (1.018 – 1.068)	.001	1.045 (1.020 – 1.070)	< .001
MELD-Na score	1.155 (1.106 – 1.207)	< .001	1.155 (1.104 – 1.209)	< .001	1.053 (1.013 – 1.095)	.009	1.049 (1.006 – 1.094)	.02
CRP (mg/dL)	1.055 (.991 – 1.124)	.10	-	-	1.035 (.976 – 1.098)	.25	-	-
Albumin (g/L)	.944 (.915 - .974)	< .001	.944 (.911 - .978)	.001	.985 (.948 – 1.023)	.43	-	-
Transferrin (g/L)	.701 (.530 – .927)	.01	1.032 (.745 – 1.431)	.85	.649 (.475 – .886)	.007	.663 (.472 – .932)	.02

Table 6. Uni- and multivariable Cox regression: iron, inflammation and hepatic function in patients without fatty liver disease (ALD or NAFLD).

	Derivation cohort				Validation cohort			
	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value	Univariable Cox regression HR (95% CI)	*P* value	Multivariable Cox regression HR (95% CI)	*P* value
	n=454				n=470			
Age (years)	1.029 (1.010 – 1,048)	.003	1.031 (1.012 - 1.051)	.001	1.045 (1.029 – 1.062)	< .001	1.040 (1.023 - 1.057)	.000
MELD-Na score	1.142 (1.099 – 1.187)	< .001	1.106 (1.057 - 1.159)	.000	1.082 (1.061 – 1.104)	< .001	1.037(1.007 - 1.068)	.014
CRP (mg/dL)	1.175 (1.086 – 1.273)	< .001	.996 (.889 - 1.116)	.940	1.085 (1.040 – 1.131)	< .001	1.022 (.964 - 1.083)	.469
Albumin (g/L)	.898 (.868 - .930)	< .001	.928 (.892 - .965)	.000	.911 (.887 - .936)	< .001	.963 (.932 - .995)	.022
Transferrin (g/L)	.311 (.211 - .458)	< .001	.613 (.395 - .950)	.029	.406 (.324 - .510)	< .001	.582 (.432 - .784)	.000

Fig. 1. Study flowchart.

Fig. 2. ROC curves: diagnostic accuracy of MELD-Na and transferrin to predict 3-month transplant-free mortality. Areas under the curves (AUC) with 95% confidence intervals are indicated. For means of comparison, transferrin is indicated in opposite test direction compared to MELD-Na.

Figure 3. Kaplan-Meier analysis: transplant-free survival according to a transferrin cutoff of 180 mg/dL in all patients (A), patients with a MELD-Na score < 15 (A) and a MELD-Na score ≥ 15 (C).

Figure 4. Correlation analysis: transferrin vs. CRP (A) and transferrin vs. albumin (B).

References

1. Brown RS, Jr., Lake JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. Am J Transplant 2005;5:203-4.
2. Habib S, Berk B, Chang CC, et al. MELD and prediction of post-liver transplantation survival. Liver Transpl 2006;12:440-7.
3. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
4. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, et al. Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival? Transpl Int 2006;19:275-81.
5. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359:1018-26.
6. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007;13:1174-80.
7. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11:336-43.
8. Weismuller TJ, Kirchner GI, Scherer MN, et al. Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology 2011;54:2114-24.
9. Walker NM, Stuart KA, Ryan RJ, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010;51:1683-91.
10. Al-Freah MA, Kriese S, Foxton MR, et al. The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome? Transpl Int 2013;26:1070-9.
11. Weismuller TJ, Manns MP, Strassburg CP. Ferritin and liver allocation? Impact on mortality not only on the waiting list but also after orthotopic liver transplantation should be considered. Hepatology 2010;52:392-3; author reply 393.
12. Bruns T, Nuraldeen R, Mai M, et al. Low serum transferrin correlates with acute-on-chronic organ failure and indicates short-term mortality in decompensated cirrhosis. Liver Int 2017;37:232-241.
13. Maras JS, Maiwall R, Harsha HC, et al. Dysregulated iron homeostasis is strongly associated with multiorgan failure and early mortality in acute-on-chronic liver failure. Hepatology 2015;61:1306-20.

14. Bergmann OM, Mathahs MM, Broadhurst KA, et al. Altered expression of iron regulatory genes in cirrhotic human livers: clues to the cause of hemosiderosis? Lab Invest 2008;88:1349-57.
15. Macedo MF, de Sousa M. Transferrin and the transferrin receptor: of magic bullets and other concerns. Inflamm Allergy Drug Targets 2008;7:41-52.
16. Ritchie RF, Palomaki GE, Neveux LM, et al. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1999;13:273-9.
17. Moirand R, Mortaji AM, Loreal O, et al. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997;349:95-7.
18. Fletcher LM, Halliday JW, Powell LW. Interrelationships of alcohol and iron in liver disease with particular reference to the iron-binding proteins, ferritin and transferrin. J Gastroenterol Hepatol 1999;14:202-14.
19. Whitfield JB, Zhu G, Heath AC, et al. Effects of alcohol consumption on indices of iron stores and of iron stores on alcohol intake markers. Alcohol Clin Exp Res 2001;25:1037-45.
20. Udell JA, Wang CS, Tinmouth J, et al. Does this patient with liver disease have cirrhosis? JAMA 2012;307:832-42.
21. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005;5:307-13.
22. Finkenstedt A, Dorn L, Edlinger M, et al. Cystatin C is a strong predictor of survival in patients with cirrhosis: is a cystatin C-based MELD better? Liver Int 2012;32:1211-6.
23. Tacke F, Nuraldeen R, Koch A, et al. Iron Parameters Determine the Prognosis of Critically Ill Patients. Crit Care Med 2016;44:1049-58.
24. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060-72.
25. Wang H, An P, Xie E, et al. Characterization of ferroptosis in murine models of hemochromatosis. Hepatology 2017.
26. Bradbury MW, Raja K, Ueda F. Contrasting uptakes of 59Fe into spleen, liver, kidney and some other soft tissues in normal and hypotransferrinaemic mice. Influence of an antibody against the transferrin receptor. Biochem Pharmacol 1994;47:969-74.
27. Ludwig J, Hashimoto E, Porayko MK, et al. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997;112:882-8.
28. Kaplan J, Craven C, Alexander J, et al. Regulation of the distribution of tissue iron. Lessons learned from the hypotransferrinemic mouse. Ann N Y Acad Sci 1988;526:124-35.

29. Liu J, Sun B, Yin H, et al. Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review. Medicine (Baltimore) 2016;95:e3150.



Study flowchart.

172x68mm (300 x 300 DPI)



	AUC (95% CI)	Cut-off	Sensitivity (%)	Specificity (%)
MELD-Na	0.86 (0.79 – 0.93)	15	84.8	64.1
Transferrin	0.83 (0.77 – 0.89)	180 mg/dL	73.9	72.7

ROC curves: diagnostic accuracy of MELD-Na and transferrin to predict 3-month transplant-free mortality. Areas under the curves (AUC) with 95% confidence intervals are indicated. For means of comparison, transferrin is indicated in opposite test direction compared to MELD-Na.

252x229mm (300 x 300 DPI)



Kaplan-Meier analysis: transplant-free survival according to a transferrin cutoff of 180 mg/dL in all patients (A), patients with a MELD-Na score < 15 (A) and a MELD-Na score ≥ 15 (C).

732x221mm (299 x 299 DPI)



Correlation analysis: transferrin vs. CRP (A) and transferrin vs. albumin (B).

571x228mm (300 x 300 DPI)